The FDA will find the flaw. We find it first. Four independent agents audit every brief and return one consensus verdict: PROCEED, DELAY, or KILL — before your organization is exposed.
When your VP of Strategy leaves, everything they knew leaves with them. Company Memory captures institutional knowledge, strategic context, and R&D intelligence — and keeps it alive through every transition.
Your competitors filed a patent yesterday. A clinical trial in your space failed last week. An FDA guidance shifted your regulatory timeline. You found out about none of them. Cortex is already watching.
FDA guidance changes don't wait for your quarterly review. They hit and your filing timeline shifts before anyone on your team reads the announcement. This module ensures you know first.
By the time a market narrative shift appears in analyst reports, the positioning window is closed. This layer detects belief divergence while there is still time to act on it.
Your board asks a question. Your team scrambles for two weeks to assemble an answer from scattered sources. The Briefing Engine delivers decision-ready intelligence on your cadence — before anyone has to ask.
Every query you run on a shared AI platform trains someone else's model. Your strategic questions become another company's dataset. This workspace is yours alone. Isolated. Private. Non-negotiable.
$12–15B repricing inside the 2025–2026 CMS LCD cycle. 86 source-cited signals across PubMed, ClinicalTrials.gov, and SEC. 30 companies under continuous SCOUT monitoring. Refreshed live.
96 source-cited signals. 49 companies under continuous SCOUT monitoring. 18% Saudi diabetes prevalence — Vision 2030 procurement live. The platform that turns indication intelligence into adversarial verification.
146 source-cited signals including 30 SEER cancer-site stat facts. 50 companies under continuous SCOUT monitoring. Population epidemiology layered on adversarial verification — only oncology pipeline carries this.
1,710 source-cited signals across PubMed, ClinicalTrials.gov, FDA, and SEC. 50 companies under continuous SCOUT monitoring across the heart-failure, AFib, and cardiometabolic frontier. Sovereign GCC procurement live.
1,692 source-cited signals. 40 companies under continuous SCOUT monitoring across the CKD, ESRD, dialysis, and transplant frontier. The DKD intersection cross-tagged with the diabetes pipeline. Five sovereign anchors.
1,679 source-cited signals. 50 companies under continuous SCOUT monitoring across the GLP-1, GIP, and MASH frontier. Manufacturing-capacity leading indicators (Catalent, Halozyme). Five sovereign anchors.
Curated digest of strategic movements, regulatory shifts, and decision-ready intelligence tailored to leadership priorities.
Side-by-side analysis of competitive assets, development timelines, and strategic positioning across your market.
Alerts when market consensus begins shifting from established belief, signaling emerging opportunity or risk.